Literature DB >> 31876866

An Assessment of Risk Factors for Herpes Simplex Virus Type 2 Infection in Malawian Women Using 2 Classifications for the HerpeSelect 2 Test.

Payal Chakraborty1, Alison H Norris, Sarah Huber-Krum2, Sarah Garver3, Robert B Hood1, Venson Banda4, Allahna Esber5, Carr Reese Patricia6, Robert Krysiak7, Abigail Norris Turner8.   

Abstract

BACKGROUND: The HerpeSelect 2 ELISA IgG test for herpes simplex virus type 2 (HSV-2) infection is widely used, convenient, and inexpensive. However, it has been shown to have lower specificity among populations in Sub-Saharan Africa compared with HSV-2 tests regarded as criterion standards.
METHODS: In 2016, we collected blood and survey data from 248 women participating in a community-based cohort study in rural Malawi (the Umoyo wa Thanzi project). Using multinomial logistic regression accounting for village-level clustering, we examined unadjusted associations between select demographic and sexual risk factors and HSV-2 serostatus. Because increasing the index value cutpoint for a positive result improves specificity, we coded HSV-2 serostatus in 2 ways: the manufacturer's recommended cutpoints (<0.9, negative; 0.9-1.1, indeterminate; >1.1, positive) and modified cutpoints with improved specificity (<0.9, negative; 0.9-3.5, indeterminate; >3.5, positive). We aimed to investigate whether associations between select risk factors and HSV-2 serostatus varied under the 2 approaches.
RESULTS: The prevalence of HSV-2 in this sample was 67% under the manufacturer's cutpoint and 22% under the modified cutpoint. Under both cutpoints, age, household size, number of marriages, and number of pregnancies were associated with HSV-2-positive serostatus. Using modified cutpoints, current bacterial vaginosis (odds ratio [OR], 3.17; 95% confidence interval [CI], 1.35-7.47), partner concurrency (OR, 4.88; 95% CI, 2.54-9.37) and unsure about partner concurrency (OR, 1.91; 95% CI, 1.08-3.38) were associated with HSV-2 seropositivity. Household size, education, and marital status were the only variables significantly associated with indeterminate HSV-2 serostatus using the modified cutpoints.
CONCLUSION: HSV-2-focused interventions informed by identifying individuals likely to have or acquire HSV-2 must be aware that different target populations may emerge depending on which cutpoints are adopted.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31876866      PMCID: PMC7816111          DOI: 10.1097/OLQ.0000000000001121

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   3.868


  22 in total

1.  Performance of HSV-2 type specific serological tests in men in Kenya.

Authors:  Musa Otieno Ng'ayo; David Friedrich; King K Holmes; Elizabeth Bukusi; Rhoda Ashley Morrow
Journal:  J Virol Methods       Date:  2009-10-23       Impact factor: 2.014

Review 2.  Risk of Bacterial Vaginosis Among Women With Herpes Simplex Virus Type 2 Infection: A Systematic Review and Meta-analysis.

Authors:  Allahna Esber; Rodolfo D Vicetti Miguel; Thomas L Cherpes; Mark A Klebanoff; Maria F Gallo; Abigail Norris Turner
Journal:  J Infect Dis       Date:  2015-01-14       Impact factor: 5.226

3.  Herpes simplex virus type 2 cross-sectional seroprevalence and the estimated rate of neonatal infections among a cohort of rural Malawian female adolescents.

Authors:  Christopher R Sudfeld; Paul C Hewett; Nadia N Abuelezam; Satvika Chalasani; Erica Soler-Hampejsek; Christine A Kelly; Barbara S Mensch
Journal:  Sex Transm Infect       Date:  2013-06-21       Impact factor: 3.519

Review 4.  Performance of commercial herpes simplex virus type-2 antibody tests using serum samples from Sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Samuel Biraro; Philippe Mayaud; Rhoda Ashley Morrow; Heiner Grosskurth; Helen A Weiss
Journal:  Sex Transm Dis       Date:  2011-02       Impact factor: 2.830

5.  Performance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries.

Authors:  Andrew Mujugira; Rhoda Ashley Morrow; Connie Celum; Jairam Lingappa; Sinead Delany-Moretlwe; Kenneth H Fife; Renee Heffron; Guy De Bruyn; Brigitte Homawoo; Etienne Karita; Nelly Mugo; Bellington Vwalika; Jared M Baeten
Journal:  Sex Transm Infect       Date:  2011-02-09       Impact factor: 3.519

6.  Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, Western blot and inhibition testing.

Authors:  J S Smith; R C Bailey; D J Westreich; I Maclean; K Agot; J O Ndinya-Achola; W Hogrefe; R A Morrow; S Moses
Journal:  Sex Transm Infect       Date:  2008-10-27       Impact factor: 3.519

Review 7.  Herpes simplex virus type 2 transmission: risk factors and virus shedding.

Authors:  Anna Wald
Journal:  Herpes       Date:  2004-08

8.  Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations.

Authors:  R Ashley-Morrow; J Nollkamper; N J Robinson; N Bishop; J Smith
Journal:  Clin Microbiol Infect       Date:  2004-06       Impact factor: 8.067

Review 9.  Incidence of herpes simplex virus type 2 infections in Africa: a systematic review.

Authors:  Sharanya Rajagopal; Amalia Magaret; Nelly Mugo; Anna Wald
Journal:  Open Forum Infect Dis       Date:  2014-07-11       Impact factor: 3.835

10.  Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012.

Authors:  Katharine J Looker; Amalia S Magaret; Katherine M E Turner; Peter Vickerman; Sami L Gottlieb; Lori M Newman
Journal:  PLoS One       Date:  2015-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.